After closing of the trading day on October 31, 2017, Europlasma granted 152,405,521 warrants (BSAR C) for the benefit of the company’s shareholders on the basis of one BSAR C for one Europlasma ordinary share registered, giving the right to subscribe for a total of 38,101,380 new shares.
